Literature DB >> 16407880

Pivotal role of xanthine oxidase in the initiation of tubulointerstitial renal injury in rats with hyperlipidemia.

W Gwinner1, H Scheuer, H Haller, R P Brandes, H-J Groene.   

Abstract

Hyperlipidemia can induce or aggravate renal tubulointerstitial injury. Experiments in a complex rat model with chronic glomerulonephritis and long-standing, coexisting hyperlipidemia suggested that induction of xanthine oxidase (XO), with increased oxygen radical generation, is involved in aggravation of tubulointerstitial injury. To separate the role of XO in the initial events of lipid-mediated tubulointerstitial injury, short-term experiments with diet-induced hyperlipidemia over 21 and 35 days were performed in otherwise healthy rats. XO expression in relation to the antioxidant enzymes was examined in the cortical tubulointerstitium (TIS) and proximal tubules (PT). Subsequent experiments with XO inhibition were performed, examining tubulointerstitial infiltration with ED1-positive cells and expression of adhesion molecules and monocyte chemoattractant protein-1 (MCP-1) as indicators of early injurious events. Hyperlipidemia increased XO activity in TIS by 40 and 86%, and in PT by 28 and 90% at days 21 and 35, compared with controls on regular diet. This increased activity was associated with increased reactive oxygen species. Among the antioxidant enzymes, glutathione peroxidase activity increased in TIS by 40% and in PT by 90%. Histological evaluation showed a three-fold increase in ED1-positive cells and increased MCP-1 and vascular cell adhesion molecule-1 (VCAM-1) expression at day 35 in the TIS. Inhibition of XO prevented tubulointerstitial ED1 cell infiltration, together with a decreased expression of MCP-1 and VCAM-1. These results point to an important role for XO in the early stage of hyperlipidemia-associated renal injury, mediating macrophage infiltration by a putatively redox-dependent upregulation of MCP-1 and VCAM-1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407880     DOI: 10.1038/sj.ki.5000121

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules.

Authors:  Toshio Ohtsubo; Kiyoshi Matsumura; Kanae Sakagami; Koji Fujii; Kazuhiko Tsuruya; Hideko Noguchi; Ilsa I Rovira; Toren Finkel; Mitsuo Iida
Journal:  Hypertension       Date:  2009-08-10       Impact factor: 10.190

Review 2.  Uric acid as a target of therapy in CKD.

Authors:  Diana I Jalal; Michel Chonchol; Wei Chen; Giovanni Targher
Journal:  Am J Kidney Dis       Date:  2012-10-09       Impact factor: 8.860

3.  Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.

Authors:  Hiroshi Kataoka; Toshio Mochizuki; Mamiko Ohara; Yuki Tsuruta; Naomi Iwasa; Rie Yoshida; Ken Tsuchiya; Kosaku Nitta; Kenjiro Kimura; Tatsuo Hosoya
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.996

4.  The role of xanthine oxidase in hemodialysis-induced oxidative injury: relationship with nutritional status.

Authors:  Dijana Miric; Bojana Kisic; Radojica Stolic; Bratislav Miric; Radoslav Mitic; Snezana Janicijevic-Hudomal
Journal:  Oxid Med Cell Longev       Date:  2013-06-02       Impact factor: 6.543

5.  The Crucial Role of Xanthine Oxidase in CKD Progression Associated with Hypercholesterolemia.

Authors:  You-Jin Kim; Se-Hyun Oh; Ji-Sun Ahn; Ju-Min Yook; Chan-Duck Kim; Sun-Hee Park; Jang-Hee Cho; Yong-Lim Kim
Journal:  Int J Mol Sci       Date:  2020-10-09       Impact factor: 5.923

6.  Hyperuricemia and chronic kidney disease: to treat or not to treat.

Authors:  Federica Piani; Fumihiko Sasai; Petter Bjornstad; Claudio Borghi; Ashio Yoshimura; Laura G Sanchez-Lozada; Carlos Roncal-Jimenez; Gabriela E Garcia; Ana Andres Hernando; Gabriel Cara Fuentes; Bernardo Rodriguez-Iturbe; Miguel A Lanaspa; Richard J Johnson
Journal:  J Bras Nefrol       Date:  2021 Oct-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.